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Abstract
Moxifloxacin is a newer-generation synthetic fluoroquinolone that is used for treatment of acute
bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, intra-
abdominal infections and skin/skin structure infections. We describe a case of fatal hepatotoxicity
caused by Moxifloxacin in a 72-year-old man. He presented with jaundice and epigastric tenderness
that started one week after being treated for acute exacerbation of his chronic bronchitis with
Moxifloxacin by his primary care physician. He was admitted to intensive care unit for close
monitoring. His labs showed marked elevation in liver enzymes and bilirubin. His condition continued
to deteriorate in intensive care unit despite supportive care. Acute hepatic failure which resulted in
his death was attributed to idiosyncratic reaction to Moxifloxacin.
Introduction
Moxifloxacin is a newer-generation (4th generation)
synthetic fluoroquinolone that is used for treatment of
acute bacterial sinusitis, acute exacerbation of chronic
bronchitis, community acquired pneumonia, intra-
abdominal infections and skin/skin structure infections
[1].It isbroad spectrum andcovers both grampositive and
gram negative bacteria and acts by inhibiting bacterial
topoisomerase II (DNA gyrase) and topoisomerase IV.
Moxifloxacin is metabolized mainly in liver via glucur-
onide and sulfate conjugation. Cytochrome P450 system
is not involved and thus there are few drug-drug
interactions associated with Moxifloxacin. It has been
known to cause common side effects like nausea, diarrhea,
dizziness and some rare side effects like anaphylaxis,
hypersensitivity reactions, nephrotoxicity, hepatotoxicity,
colitis, tendon rupture, serum sickness and QTc prolonga-
tion [1]. There is very scant literature on severe hepato-
toxicity caused by Moxifloxacin [2,3] and even fewer case
reports of fatal hepatotoxicity caused by the same. We
report a rare case of fatal hepatotoxicity caused by
Moxifloxacin in a 72-year-old man.
Case presentation
A 72-year-old Caucasian man was brought to the ER with
symptoms of generalized weakness, increasing fatigue, leg
swelling and jaundice for past 10 days. He was recently
treated for acute exacerbation of his chronic bronchitis
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by his primary care physician. A week following treatment,
his wife noticed yellowing of his eyes and skin. He denied
any fever, sick contacts, any recent travel within or outside
United States or history of insect bites. His past medical
history was significant for COPD, rheumatoid arthritis and
remote history of squamous cell carcinoma of the skin.
Family history was significant for bone cancer, breast
cancer, AAA and stroke. Patient quit smoking 40 years ago;
he drinks alcohol very rarely and denied illicit drug use.
His home medications included Tiotropium bromide
handihaler, Salmeterol/Fluticasone inhaler, albuterol (sal-
butamol) inhalers, folic acid and low dose methotrexate
for rheumatoid arthritis.
Patient was admitted to ICU for close monitoring due to
his multiple medical comorbidities. On exam, at time of
presentation his vitals were normal; he was not in acute
distress. Scleral icterus was seen. His chest and cardiac
exam was normal. Abdomen exam revealed mild RUQ
and marked epigastric tenderness. He had bilateral pitting
pedal edema. No petechiae or purpura were seen.
His labs showed a WBC of 2.6, Hb 11.2, hematocrit 32.3,
platelet 13000, peripheral blood smear showed pancytope-
nia without atypical cells, blood cultures × 5 days were
negative, LDH 169, BUN 72, Cr 2.8, Na
+ 134, K
+ 5.2, AST
150,ALT193,alkalinephosphatase337,totalbilirubin29.0,
CO218,totalprotein 4.4,albumin 2.8,CRP 0.7,ESR 5,and
ammonia 29. Serum lipase and amylase were normal.
Infectious diseases staff was consulted considering infection
as the likely explanation. HIV, Hepatitis A, B and C panel,
IgG CMV, Monospot, urine Ag for Histoplasmosis, Quanti-
feron TB Gold and serology for leptospira were all negative.
Platelet antibody, heavy metal screen for arsenic, lead and
mercury were negative. Hematology-Oncology service was
consultedforpancytopenia.SerumvitaminB12,RBCfolate,
methylmalonic acid levels were within normal limits. Bone
marrow biopsy was done and it was negative for any
lymphoma/leukemia or myelophthisic process. Bacterial
and fungal cultures on bone marrow were also negative.
CT scan abdomen and pelvis showed mild splenomegaly,
non obstructive gallstones without cholecystitis. It was
negative for masses, lymph nodes, ascites or any process
suggestive of sepsis or hepatic failure.
His liver function continued to deteriorate over days
despite full supportive care in ICU. His methotrexate was
held in light of deranged liver enzymes. Following this
extensive workup, his acute hepatic failure with blood
dyscrasia was attributed to idiosyncratic reaction to
Moxifloxacin. Patient died during his stay in ICU due to
overwhelming multi-organ system failure.
Discussion
More than 600 drugs have been implicated in causing liver
disease. In United States, more than 20% cases of jaundice
in elderly are caused by drugs. Diagnosis of drug induced
liver injury (DILI) is based on finding elevated liver
enzymes or development of hepatitis like symptoms,
jaundice which cannot be explained due to any other
cause. Most cases occur within 1 week to 3 months of
exposure of drug. Liver damage may present as acute
hepatocellular injury, cholestatic injury, granulomatous
hepatitis, vascular insult, chronic hepatitis or neoplastic
lesion [4].
Idiosyncratic drug reactions are responsible for 13% of
acute liver failure in the United States. Antibiotics are the
most common cause of DILI. There is 10% mortality
associated with drug induced hepatocellular jaundice [5].
Liver injury is described as:
￿ ALT (SGPT) > 3 times upper limit of normal or
￿ Alkaline phosphatase > 2 times upper limit of normal or
￿ Total bilirubin > 2 times upper limit of normal AND
increased ALT or increased alkaline phosphatase
Drug induced liver injury (DILI) categories are based on
calculation of ratio of ALT to alkaline phosphatase [5]. It is
subdivided as follows:
￿ Hepatocellular if R ≤ 5
￿ Cholestatic if R ≤ 2
￿ Mixed if 2 ≤ R ≤ 5
where R ¼
ALT=ðupper limit normalÞ
Alk Phos=ðupper limit NLÞ
DILI is a diagnosis of exclusion. There is temporal
associationbutnospecificbiochemicalorhistologicpattern
whichispathognomonicforDILI.Druginducedliverinjury
shows improvement with discontinuation of the drug.
Dysfunctional Single Nucleotide Polymorphisms (SNP)
have been implicated in DILI susceptibility [6-8].
Idiosyncratic reactions are rare, unpredictable and not
dose dependent but can cause significant morbidity and
mortality. There have been very few case reports of hepatic
failure due to Moxifloxacin in literature [2,3]. As per
Moxifloxacin packaging insert [1] most common side
effects include nausea, vomiting, diarrhea and dizziness.
Serious adverse effects being QTc prolongation (cardio-
toxicity), convulsions, cartilage erosion, anaphylaxis,
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rupture. Some other adverse effects of Moxifloxacin
reported in medical literature include hypersensitivity
pneumonitis, immediate hypersensitivity, neutropenia,
syncope, glycemic instability and arthropathy [9-15].
Our case is an important addition to the scant medical
literature available in form of published case reports
providing evidence on Moxifloxacin induced severe
hepatotoxicity which can be fatal.
Conclusion
Primary care and critical care clinicians should use caution
in using fluoroquinolones (moxifloxacin) in patients with
pre-existing liver disease or those at risk of having liver
disease and being prompt in discontinuing this drug at
earliest signs of liver compromise as it could result in fatal
outcomes.
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